Evaluation of the effects of sound exposure and low field electromagnetism on growth and antibiotics susceptibility of some microorganisms

Garuba, Emmanuel Oluwaseun; Ajunwa, Obinna Markraphael; Ibrahim-King, Aishat Nana

doi:10.1186/s42269-021-00674-z

Bulletin of the National Research Centre

Table 1 Antibiotics susceptibility profile for selected Gram-negative bacteria as read in mean diameter of zones of inhibition (mm) after exposure to acoustic treatment at 5000 Hz/90 dB compared with control

From: Evaluation of the effects of sound exposure and low field electromagnetism on growth and antibiotics susceptibility of some microorganisms

Bacteria	CAZ	CIP	TET	IMP	AMP
S. marcescens ATCC14756	a) 26 ± 1.4* b) 17 ± 0 c) 25 ± 1.4 d) 26 ± 1.4	a) 28 ± 2.8 b) 30 ± 0.7 c) 28 ± 2.1 d) 31 ± 1.4	a) R b) R c) R d) R	a) 26 ± 1.4 b) 19 ± 2.1 c) 24 ± 1.4 d) 25 ± 0.7	a) R b) R c) R d) R
P. aeruginosa ATCC9027	a) 26 ± 1.4 b) 23 ± 0.7 c) 20 ± 1.4 d) 22 ± 0	a) 34 ± 3.5 b) 29 ± 1.4 c) 21 ± 0.7 d) 22 ± 3.5	a) R b) R c) R d) R	a) 26 ± 1.4 b) 28 ± 2.1 c) 24 ± 0.7 d) 29 ± 1.4	a) R b) R c) R d) 11 ± 1.4
G. oxydans ATCC19357	a) 27 ± 2.8 b) R c) 29 ± 1.4 d) 19 ± 4.9	a) 26 ± 0.7 b) 27 ± 3.5 c) 21 ± 2.1 d) 21 ± 0.7	a) R b) 17 ± 2.8 c) 12 ± 0.7 d) R	a) 26 ± 1.4 b) 27 ± 2.8 c) 24 ± 2.8 d) 28 ± 0.7	a) 23 ± 0.7 b) 28 ± 0.7 c) 14 ± 2.1 d) R
R. sphaeroides ATCC17023	a) 24 ± 0.7 b) 16 ± 0 c) R d) 14 ± 5.7	a) 24 ± 0.7 b) 15 ± 0 c) 20 ± 2.1 d) 18 ± 2.1	a) R b) R c) 25 ± 0.7 d) R	a) R b) 19 ± 0.7 c) 21 ± 0.7 d) 23 ± 5.7	a) R b) R c) R d) R
C. freundii ATCC33128	a) 14 ± 0.7 b) 31 ± 6.4 c) 16 ± 4.2 d) 14 ± 2.1	a) 26 ± 0.7 b) 22 ± 5.7 c) 16 ± 2.1 d) 19 ± 7.1	a) 25 ± 0 b) 12 ± 2.8 c) 15 ± 2.1 d) 20 ± 2.1	a) 29 ± 4.2 b) 30 ± 0.7 c) 28 ± 2.1 d) 32 ± 0.7	a) 30 ± 2.1 b) 21 ± 9.2 c) R d) R
Y. pestis ATCC11953	a) 13 ± 1.4 b) 13 ± 2.1 c) 15 ± 0.7 d) 13 ± 1.4	a) 25 ± 0 b) 20 ± 0.7 c) 22 ± 0.7 d) 21 ± 0.7	a) R b) R c) R d) R	a) 23 ± 1.4 b) 18 ± 5.7 c) 24 ± 1.4 d) 25 ± 0	a) 15 ± 0 b) R c) 13 ± 0.7 d) 21 ± 2.1
K. pneumoniae ATCC25923	a) 26 ± 1.4 b) 26 ± 0 c) 26 ± 1.4 d) 28 ± 5.7	a) 31 ± 2.1 b) 20 ± 1.4 c) 23 ± 3.5 d) 18 ± 1.4	a) R b) 16 ± 12.7 c) 17 ± 4.2 d) R	a) 22 ± 2.8 b) R c) 25 ± 4.9 d) 31 ± 1.4	a) 24 ± 0.7 b) 21 ± 1.4 c) 14 ± 6.4 d) R
A. aceti ATCC15973	a) 19 ± 4.2 b) 21 ± 2.8 c) 23 ± 2.8 d) 27 ± 1.4	a) 21 ± 9.9 b) 19 ± 1.4 c) 19 ± 0 d) 21 ± 2.8	a) 13 ± 4.2 b) 15 ± 9.2 c) 13 ± 1.4 d) 17 ± 0.7	a) 17 ± 1.4 b) 30 ± 2.4 c) 26 ± 0.7 d) 28 ± 0	a) 16 ± 4.2 b) R c) R d) R
E. coli ATCC25922	a) 29 ± 1.4 b) 20 ± 1.4 c) R d) 15 ± 1.4	a) 22 ± 1.4 b) 21 ± 0.7 c) 18 ± 3.5 d) 24 ± 0.7	a) 19 ± 0 b) R c) 14 ± 7.8 d) R	a) 33 ± 4.2 b) 30 ± 0.7 c) 30 ± 2.1 d) 29 ± 1.4	a) 26 ± 1.4 b) R c) R d) R

a) Control b) 24 h c) 48 h d) 72 h R—Resistance CAZ—Ceftazidime CIP—Ciprofloxacin
TET—Tetracycline IMP—Imipenem AMP—Ampicillin *Data are mean of replicate ± Standard deviation

Back to article page